Article · News
Retatrutide peptide – what South Africans need to know
Illegal retatrutide peptide on the South African market
Medical Brief reported on 21 October 2026 that unregistered obesity medicines such as retatrutide are being sold “openly and brazenly” in South Africa by social-media influencers, gym instructors and even hairdressers. The drug has not been approved by the South African Health Products Regulatory Authority (SAHPRA) or any other regulator.
Bootleg retatrutide linked to two US deaths
The US Food and Drug Administration logged two fatal reports involving bootleg retatrutide. The first, in July, involved a 41-year-old woman who suffered cardiac arrest after obtaining the product from an unreliable source. The second, in September, involved a 49-year-old patient who died after a licensed nurse persuaded her to purchase the peptide from an online vendor; she experienced severe dehydration, malnutrition and cardiac arrest. Medical Brief noted on 21 October 2026 that these reports do not prove causation but highlight the dangers of an illicit market.
South Africans injecting the illicit peptide
News24 highlighted on 24 October 2026 that South Africans are already injecting the unapproved drug, referring to it as “Reta”. The article featured personal stories of users who believe the weight-loss results outweigh the perceived risks, despite the lack of medical supervision.
Safety concerns from laboratory testing
CBS News, on 21 October 2026, bought two samples labelled as retatrutide. Laboratory analysis revealed one vial contained only phenylacetic acid – a fragrance filler – and the other was contaminated with bacteria. Experts warned that injecting such material could cause serious infection or other health complications.
Regulatory and industry response
South African pharmaceutical leaders, including the Pharmaceutical Task Group chair Dr Stavros Nicolaou, have urged authorities to prosecute sellers of the illegal peptide. The same Medical Brief article (21 October 2026) noted that Eli Lilly plans to submit a US FDA application for retatrutide in the first quarter of next year, but no approval exists locally.
What this means for South African consumers
With GLP-1 demand driving pharmacy revenue – Dis-Chem reported a 10% rise in dispensary revenue through August 2026 – the appetite for weight-loss drugs is high. However, the high cost of approved GLP-1 medicines (R3 000–R6 000 per month) has pushed some people toward unregulated options, as described by The National on 10 November 2026.
Consumers should be aware that any retatrutide purchased outside the formal healthcare system is not guaranteed to be the authentic product, may be contaminated, and could pose serious health risks. Until SAHPRA grants approval, the safest route remains to avoid illicit sources and seek professional medical advice for weight-loss treatment.
Frequently asked questions
What is retatrutide?
Retatrutide is an experimental triple-hormone agonist being studied as a next-generation obesity treatment; it is still in clinical trials and not approved in South Africa.
Is retatrutide legal in South Africa?
No, retatrutide has not been approved by the South African Health Products Regulatory Authority (SAHPRA) and is considered an unregistered medicine.
Where are people obtaining retatrutide in South Africa?
It is being sold illegally through social-media influencers, gym instructors, hairdressers and online vendors, often marketed under the name “Reta”.
What risks are associated with buying illicit retatrutide?
Samples have been found to contain only filler substances or bacterial contamination, and bootleg versions have been linked to severe dehydration, malnutrition, cardiac arrest and two reported US deaths.
How much do approved GLP-1 medicines cost compared to illicit retatrutide?
Approved GLP-1 medicines cost roughly R3 000–R6 000 per month, which drives some consumers to seek cheaper, unregulated alternatives like retatrutide.
What should consumers do if they are considering weight-loss treatment with retatrutide?
They should avoid illicit sources, seek professional medical advice, and wait for SAHPRA approval before using the peptide.
Sources
- medicalbrief.co.za, "SA call for action against illegal obesity medicines suspected in US deaths", 2026-10-21, https://www.medicalbrief.co.za/sa-call-for-action-against-illegal-obesity-medicines-suspected-in-us-deaths
- news24.com, "A Reta revolution or Russian roulette? The illicit weight-loss drug South Africans are injecting", 2026-10-24, https://www.news24.com/southafrica/news/a-reta-revolution-or-russian-roulette-the-illicit-weight-loss-drug-south-africans-are-injecting-20261024-0812
- cbsnews.com, "We bought and tested what was sold as an experimental weight loss drug. The lab results were "pretty terrifying."", 2026-10-21, https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results
- bloomberg.com, "GLP-1 Demand Boosts Dis-Chem’s South Africa Pharmacy Revenue", 2026-10-30, https://www.bloomberg.com/news/articles/2026-10-30/glp-1-demand-boosts-dis-chem-s-south-africa-pharmacy-revenue
- thenational.co.za, "SA employers start subsidising staff on GLP-1 weight-loss medication", 2026-11-10, https://thenational.co.za/news/2026-11-10-sa-employers-start-subsidising-staff-on-glp-1-weight-loss-medication